Last week, COMPASS Pathways announced that it acquired an intellectual property (IP) portfolio of novel psychedelic compounds and prodrugs. According to the press release, “The substances covered in the IP portfolio include a variety of psychedelic and empathogenic compounds, some of which are prodrugs.” COMPASS’s press release defined prodrugs as “pharmacologically inactive compounds which are…
